At the time of writing, Transmedics Group Inc [TMDX] stock is trading at $151.51, up 6.50%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TMDX shares have gain 3.78% over the last week, with a monthly amount glided 1.71%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on June 06, 2024, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $161. Previously, Stephens started tracking the stock with Overweight rating on June 04, 2024, and set its price target to $151. On March 28, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $95 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating. JP Morgan upgraded its rating to a Overweight but $48 remained the price target by the analyst firm on August 02, 2022. JP Morgan downgraded its rating to Neutral for this stock on October 08, 2020, but kept the price target unchanged to $15. In a note dated April 07, 2020, Oppenheimer initiated an Outperform rating and provided a target price of $25 on this stock.
For the past year, the stock price of Transmedics Group Inc fluctuated between $36.42 and $156.05. Currently, Wall Street analysts expect the stock to reach $146.67 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $151.51 at the most recent close of the market. An investor can expect a potential drop of -3.19% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
According to Transmedics Group Inc [NASDAQ:TMDX], the company’s sales were 296.92M for trailing twelve months, which represents an 133.07% jump. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -0.0%, Pretax Profit Margin comes in at 0.0%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.02 and Total Capital is -0.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 144.13 points at the first support level, and at 136.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 165.43, and for the 2nd resistance point, it is at 179.36.
Ratios To Look Out For
It is important to note that Transmedics Group Inc [NASDAQ:TMDX] has a current ratio of 9.72. Also, the Quick Ratio is 8.76, while the Cash Ratio stands at 6.68. Considering the valuation of this stock, the price to sales ratio is 16.81, the price to book ratio is 31.21.
Transactions by insiders
Recent insider trading involved Tamer Khayal, Officer, that happened on Aug 01 ’24 when 8876.0 shares were purchased. President & CEO, Hassanein Waleed H completed a deal on Jul 15 ’24 to sell 8625.0 shares. Meanwhile, Chief Commercial Officer Khayal Tamer I sold 2958.0 shares on Jul 01 ’24.
